BIOA vs CAH: fair value comparison
BioAge Labs, Inc. and Cardinal Health, Inc. · Updated 2026-10-19
BIOA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BIOA currently ranks higher by quality score.
| BIOA | CAH | |
|---|---|---|
| Verdict | No estimate yet | Overvalued |
| Last price | $4.84 | $237.57 |
| 12-month range | $4.84–$25.10 | $159.16–$254.06 |
| Rank by discount to fair value | — | #75 of 108 Healthcare |
| Rank by quality score | #180 of 301 Healthcare | #181 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | — | Modest |
| RSI zone | Oversold | Overbought |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Fairly Valued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: BIOA fair value analysis · CAH fair value analysis